TRMX Company Profile

For the fiscal span ending December 31 2022 Iqiyi Inc reached zero gain of $0.00 per share compare to $0.00 a year ago and from $0.00 per share from the prior reporting period.

Sales decreased in double digits by -12.314 % to $4.20 billions from $4.79 billions in the corresponding reporting period a year ago and sequentially from $0.00 millions.

Sales have tumbled at Telesis Bio Inc during the fiscal fourth quarter of 2022

Telesis Bio Inc announced disappointing fiscal fourth quarter of 2022, where Sales melted down by -41.976 % to $9.47 millions and the Laboratory Analytical Instruments company recorded net deficit per share to $-0.28, relative to $-0.58, in the fiscal span ending December 31 2021.

Existing costs were on the rise at the company in the fiscal interval closing December 31 2022

The shareholders haven't hoped for some changes at the business all over the earnings cycle of fiscal October to December 31 2022 period at the PYXS. But, they monitor the company's operating deficit which was at $-37.973 millions, during the matching time.

The company disclosed operating shortfall in the fourth quarter of 2022

The shareholders did not expect any changes at the top-line during the the October to December 31 2022 reporting season at the company. But, stockholders observe INZYs' operating shortfall that came in at $-19.533 millions, in the same period.

For the fiscal fourth quarter of 2022 company reached zero gain of $0.00 per share compare to $0.00 a year before and from $0.00 per share from the previous financial reporting period.

Sales were up by 11.221 % to $3.51 billions from $3.16 billions in the corresponding financial reporting period a year before and sequentially Sales Tumbled from $0.00 millions.